Addus HomeCare (ADUS) Stephens 26th Annual Investment Conference | NASH2024 summary
Event summary combining transcript, slides, and related documents.
Stephens 26th Annual Investment Conference | NASH2024 summary
13 Jan, 2026Election and regulatory environment
Confident in business resilience regardless of election outcome; both parties present unique opportunities and challenges.
Anticipates Medicaid Access Rule may be repealed under a Trump administration, seen as a tailwind.
Medicare Advantage growth could pressure home health margins, but impact is limited due to small business share.
No significant direct labor impact expected from immigration policy changes; some potential for wage inflation.
Strategic focus and capital allocation
Personal care remains the core business, expected to reach 80% of mix post-Gentiva acquisition.
Texas is a key growth market, with plans to expand personal care, home health, and hospice services.
M&A strategy prioritizes personal care and home health, with hospice as a secondary focus.
Conservative M&A approach, focusing on strategic fit and price, with flexibility for creative deals.
Growth outlook and M&A pipeline
Long-term target of 10%+ revenue growth, with 3-5% organic growth in personal care and mid-single digits in clinical services.
M&A expected to contribute about half of total growth; pipeline includes opportunities across all segments.
Multiples for personal care and home health remain stable; hospice assets command higher valuations.
Strategic alignment with personal care network is key for evaluating larger deals.
Latest events from Addus HomeCare
- Hospice recovery, census growth, and tech-driven hiring fuel expansion amid stable rates.ADUS
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Strong Q4 exit, tech-driven efficiency, and robust growth outlook amid regulatory changes.ADUS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Margins, growth, and M&A drive performance as census rebounds and tech boosts fill rates.ADUS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q4 2025 revenue and EBITDA surged, led by personal care and hospice growth.ADUS
Q4 202524 Feb 2026 - Growth driven by acquisitions, tech, and value-based care, with census recovery expected by 2026.ADUS
Jefferies 2025 Healthcare Services Conference3 Feb 2026 - Q2 revenue up 10.4%, net income $18.1M, major equity raise, Gentiva deal, NY divestiture.ADUS
Q2 20242 Feb 2026 - Strong growth, strategic market exits, and value-based care drive expansion and resilience.ADUS
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 revenue up 7%, EPS up 13%, with Gentiva deal and NY exit to drive future growth.ADUS
Q3 202416 Jan 2026 - Strong growth, smooth integration, and favorable labor trends set up a robust 2025.ADUS
KeyBanc Annual Healthcare Forum 202526 Dec 2025